×
Kamada Pre-Tax Income 2012-2024 | KMDA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Kamada pre-tax income from 2012 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
View More
Kamada Pre-Tax Income 2012-2024 | KMDA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Kamada pre-tax income from 2012 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$172.8B
Vertex Pharmaceuticals (VRTX)
$125.8B
Regeneron Pharmaceuticals (REGN)
$111.1B
Bristol Myers Squibb (BMY)
$108.2B
Gilead Sciences (GILD)
$108B
CSL (CSLLY)
$97B
GSK (GSK)
$81.3B
Alnylam Pharmaceuticals (ALNY)
$38.6B
Argenex SE (ARGX)
$32.3B
BioNTech SE (BNTX)
$28B
Biogen (BIIB)
$27.5B
Illumina (ILMN)
$22.9B
Moderna (MRNA)
$22.1B
BeiGene (BGNE)
$21.6B
Genmab (GMAB)
$15B
BioMarin Pharmaceutical (BMRN)
$13.3B
Insmed (INSM)
$13.2B
Vaxcyte (PCVX)
$13.2B
Exact Sciences (EXAS)
$13B
Incyte (INCY)
$12.7B
Sarepta Therapeutics (SRPT)
$12B
Bio-Techne Corp (TECH)
$11.4B
QIAGEN (QGEN)
$9.9B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.9B
Revolution Medicines (RVMD)
$8.4B
Exelixis (EXEL)
$8.4B
Intra-Cellular Therapies (ITCI)
$8B
Legend Biotech (LEGN)
$8B
Ascendis Pharma (ASND)
$7.9B